Drug major Lupin today posted 55.11 per cent rise in its consolidated net profit at Rs 630.04 crore for the second quarter ended September 30, driven by robust sales in the US, Japan and domestic market.
The Mumbai-based company had posted a net profit of Rs 406.18 crore during the same period of previous fiscal.
Net sales of the company rose to Rs 3,116.81 crore for the second quarter, as against Rs 2,631.46 crore during the same period of previous fiscal, the company said in a statement.
For the half year ended September 30, the company posted a net profit of Rs 1,254.78 crore, against Rs 807.24 crore in the year ago period, an up by 55.44 per cent.
Net sales of the company for the half year ended September 30, rose to Rs 6,400.76 crore, as compared to Rs 5,052.12 crore in the same period of previous fiscal.
Commenting on the result, Lupin Ltd Managing Director Nilesh Gupta said: "We have had a great first half driven by strong growth in US, India, Japan and our API business. Our research pipeline is evolving well and we expect significant developments in the dermatology and inhalation space in the quarters to come".
Lupin shares were trading at Rs 1,377.55 apiece on the BSE, down 1.18 per cent from its previous close.
